Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
COVID-19: early-phase trial registry
68 of 299 indexed COVID-19 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #30 of 28,707 conditions by registered trial count.
299 US clinical trials · 68 currently recruiting · #30 of 28,707 conditions by registered trial count
COVID-19: 299 US clinical trials tracked, 68 recruiting.
COVID-19 is the subject of 299 registered US clinical trials on ClinicalTrials.gov, 68 of them currently open to new participants. 42 are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most active sponsor is National Institute of Allergy and Infectious Diseases (NIAID), running 16 of these trials.
Enrollment posture brief
Registry condition covid-19
OPEN 68 | RECR 23% | LATE 42 | EARLY 83 | RANK #30 | SPON 16
Volume-matched condition peers
Nearest open-share peer: Hypogonadism (23% recruiting · 22 trials)
COVID-19 lists 68 open slots (23% of 299 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for COVID-19 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
COVID-19 is recruiting below its size-band peers.
68 of 299 indexed trials (22.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of COVID-19 trials is spread across many organizations.
National Institute of Allergy and Infectious Diseases (NIAID) accounts for 16 of 299 trials (5.4%). 173 distinct sponsors appear on at least one study for this condition label.
-
Typical COVID-19 enrolment sits around 245 participants.
Median target enrolment is 245 among the 299 trials that report a genuine target (sentinel values excluded). 96 of those (32.1%) plan for fewer than 100 participants.
-
COVID-19 splits between interventional and observational designs.
196 interventional and 103 observational studies make up this index (65.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
299 total, page 5 of 6
Evaluation of the RD-X19 Treatment Device in Individuals With Mild COVID-19
EmitBio
NCT05817045
A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit
Lucira Health
NCT04720235
Seroprevalence of SARS CoV 2 Antibodies in Previously Undiagnosed Healthcare Workers
Mayo Clinic
NCT04383587
A Retrospective Study of COVID-19 Treatments
ProgenaBiome
NCT04949230
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
University of California, Los Angeles
NCT04904510
Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning
Dascena
NCT04423991
A Study of S-892216 in Participants With COVID-19
Shionogi
NCT06928051
COVID-19 Testing and Vaccination Among Spanish Speakers
Wake Forest University Health Sciences
NCT05302908
SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding
University of Wisconsin, Madison
NCT04478019
Clinical Performance Evaluation of SARS-CoV-2 (COVID-19) Antigen Assay in Point of Care Settings
Freedom For All Diagnostics
NCT05213897
A Study to Evaluate EDP-235 in Non-hospitalized Adults With COVID-19
Enanta Pharmaceuticals
NCT05616728
A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)
Kinevant Sciences
NCT04351243
Proning Early in Awake COVID-19 Hypoxic Respiratory Failure (PREACHR) Study
New York Hospital Queens
NCT05130541
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
Pulmotect
NCT04313023
ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)
NCT04988035
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
BeiGene
NCT04551898
A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection
NYU Langone Health
NCT04343989
Post COVID-19 Vaccination Analysis in Healthcare Worker Recipients
Huntington Memorial Hospital
NCT04922944
COVID-19 Endoscopy Survey
Al-Azhar University
NCT04342637
A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection
TriHealth
NCT04392232
Index Individuals in SARS-CoV-2 Prevention Research Studies (COVID-19 Index Individuals Companion Study)
University of Washington
NCT05074719
Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019
University of Pennsylvania
NCT04338009
Northern Colorado COVID-19 Biobank
Colorado State University
NCT04603677
Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Massachusetts General Hospital
NCT04830046
Impact of Colchicine and Low-dose Naltrexone on COVID-19
HealthPartners Institute
NCT04756128
Clinical Evaluation of a Point-of-Care (POC), COVID-19 Rapid Antigen Test (CoviDx™)
Lumos Diagnostics
NCT04750629
PREP (Pre-Exposure Prophylaxis) of COVID-19
Ghady Haidar
NCT05461378
COVID-19 Project ECHO in Nursing Homes
Milton S. Hershey Medical Center
NCT04499391
NOWDx Test for the Detection of Antibodies to COVID-19
NOWDiagnostics
NCT04690413
Assessment of Exam Findings in Coronavirus Disease 2019 (COVID-19) With Point-of-Care Ultrasonography (POCUS)
University of Minnesota
NCT04339998
Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients
Golden Biotechnology Corporation
NCT04523181
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
GlaxoSmithKline
NCT05972993
Coronavirus Disease of 2019 (COVID-19) Health Education Initiative for School Safety
University of Miami
NCT06938230
ReSET Aim 1b: Restarting Safe Education and Testing for Children With Medical Complexity - COVID-19 Testing in School With Children and Staff
University of Wisconsin, Madison
NCT04899245
Comparing the Effects of Different Doses of Dexamethasone to Treat Inpatient COVID-19
University of Oklahoma
NCT04707534
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Eli Lilly and Company
NCT04701658
A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults
GlaxoSmithKline
NCT06680375
Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reaction
University of Michigan
NCT05212610
Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19
Metro Infectious Disease Consultants
NCT04438057
KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers
KBio
NCT04473690
A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion
Lucira Health
NCT04720794
Safe and Healthy Schools
University of Wisconsin, Madison
NCT05105789
Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants
GlaxoSmithKline
NCT05260437
Aggrenox To Treat Acute Covid-19
Rutgers, The State University of New Jersey
NCT04410328
Evaluate Long Term Cardiovascular and Pulmonary Complications After COVID-19 With Point of Care Ultrasound
University of Louisville
NCT04756193
Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19
Columbia University
NCT04367831
Rapid, Onsite COVID-19 Detection
University of Wisconsin, Madison
NCT04460690
Augmentation of Immune Response to COVID-19 mRNA Vaccination Through OMT With Lymphatic Pumps
Western University of Health Sciences
NCT04928456
Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19
Vanderbilt University Medical Center
NCT04347538
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
National Institute of Allergy and Infectious Diseases (NIAID)
NCT06729593
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 28 |
| Phase 2 | 55 |
| Phase 3 | 31 |
| Phase 4 | 11 |
Top Sponsors
Named interventions
Most-linked intervention names on COVID-19 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on COVID-19 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this COVID-19 page
299 registered trials, 68 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 68 COVID-19 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Institute of Allergy and Infectious Diseases (NIAID) sponsors the most COVID-19 trials on record, review their full trial history before evaluating a specific study. See National Institute of Allergy and Infectious Diseases (NIAID)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This COVID-19 condition card totals 299 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.